The Amaze trial aims to investigate the use of Lariat for catheter-based left atrial appendage closure in patients with persistent atrial fibrillation, the Redwood City, Calif-based company said.
SentreHeart touted recent studies that show Lariat can mechanically close left atrial appendages and can isolate electrical activity, a known contributor for atrial fibrillation.
The company won 510(k) clearances from the FDA in 2006, 2009, and 2014. Last year, Variant won CE Mark approval in the European Union.
“We are excited to have Deerfield as an investment partner in SentreHeart,” CEO & president Russ Seiber said in prepared remarks. “Our objective is to address improved treatment strategies for AFib of which the LAA plays a critical role in the restoration and maintenance of normal sinus rhythm, as well as, protection against thromboembolism. The Amaze trial is key to fulfilling our commitment to developing clinical evidence with potential to significantly improve the lives of patients with atrial fibrillation.”
“We are very pleased to support SentreHeart and the landmark Amaze trial. The Lariat technology addresses the clinical needs and requirements for LAA closure in AFib patients with advantages unmatched by other closure options,” Deerfield partner Ted Huber added. He was appointed to SentreHeart’s board of directors, according to the company. “The technology developed by SentreHeart is creating a new path to improved outcomes in the treatment of AFib, as well as redefining the clinical role of LAA closure.”
The post SentreHeart closes $35m Series D for Lariat trial appeared first on MassDevice.
from MassDevice http://ift.tt/2dhRjQm
Cap comentari:
Publica un comentari a l'entrada